TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01852097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
Description: The general approach to the intervention is the following:~1. Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~2. Give feedback to individuals on their questionnaire responses.~3. Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~4. Provide advice on overcoming practical barriers.~5. Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~6. Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation.
Study: NCT01766336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 ELND005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 ELND005
Study: NCT04190342

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tai chi group
Description: Around 60 minutes practising easy tai chi movements/postures twice per week
Study: NCT05266599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA Fillapex root canal sealer
Description: Root canal treatments were performed with MTA Fillapex
Study: NCT03027011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
Study: NCT05266599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AH Plus root canal sealer
Description: Root canal treatments were performed with AH plus
Study: NCT04362215

Intervention type: DIAGNOSTIC_TEST
Intervention: Subjective accomodation amplitude measurement
Description: ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))

Intervention type: DIAGNOSTIC_TEST
Intervention: Subjective accomodation amplitude measurement
Description: ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
Study: NCT04128839

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia berry juice
Description: A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
Study: NCT02783755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: smartphone
Description: Coping Skills Training for pain will be delivered to participants using video-conferencing
Study: NCT00753012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
Study: NCT01418664

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D Max drops
Description: Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
Study: NCT00427583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT02768649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: Sequential dosing of each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: Sequential dosing of each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: Sequential dosing of each cohort
Study: NCT03027011

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group without remote ischemic preconditioning
Study: NCT05037344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy
Description: The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral psychotherapy
Description: The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
Study: NCT03794180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ003234
Description: Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
Study: NCT03794180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
Study: NCT00366353

Intervention type: OTHER
Group type: OTHER
Intervention: Sedation during SBT

Intervention type: OTHER
Group type: OTHER
Intervention: No sedation
Study: NCT02665130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai-chi plus Indacaterol
Description: Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary rehabilitation plus Indacaterol
Description: Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
Study: NCT00943735

Intervention type: DRUG
Intervention: Fesoterodine
Description: Fesoterodine 4 mg and 8 mg QD

Intervention type: BEHAVIORAL
Intervention: Your Way
Description: early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
Study: NCT02768649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
Study: NCT01082718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine Artesunate
Description: Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine Artesunate
Description: Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
Study: NCT00819533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sensor (ActiSight™ Needle Guidance System)
Description: Patients will have their lung sample obtained under CT and ActiSight needle guidance system
Study: NCT04132024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Study: NCT03920826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation
Description: The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
Study: NCT03531853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand-held swept source optical coherence tomography
Description: images the eye
Study: NCT02054455

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei F19
Description: 25x10E9 live bacterial cells for 3 days/week for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei F19
Description: 25x10E9 live bacterial cells for 3 days/week for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei F19
Description: 25x10E9 live bacterial cells for 3 days/week for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
Study: NCT04602052

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation and evacuation
Description: Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilation and evacuation
Description: Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
Study: NCT04795050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project POWER
Description: Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
Study: NCT02556892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
Study: NCT04126954

Intervention type: OTHER
Intervention: Serum PTH concentrations results
Description: To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
Study: NCT00697216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study: NCT00699478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecobalamin
Description: Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
Study: NCT00627471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.
Study: NCT02873156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2027 matched placebo
Description: Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
Study: NCT03386773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 16-week program
Description: 16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16-week program
Description: 16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient generated health data
Description: Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
Study: NCT03274778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 20 MG
Description: tablets
Study: NCT03573258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber or Placebo (depending on the randomization)
Description: ingestion of dietary fibers prior to meal intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber or Placebo (depending on the randomization)
Description: ingestion of dietary fibers prior to meal intake
Study: NCT02909049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIDAZOLAM
Description: Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEPIVACAÍNE
Description: Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FENTANILE
Description: Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KETAMINE
Description: Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
Study: NCT02393716

Intervention type: DEVICE
Group type: OTHER
Intervention: Endurant Evo AAA Stent Graft System

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular aneurysm repair (EVAR)
Study: NCT02306343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPad
Description: The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
Study: NCT03097016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
Study: NCT04097418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training compared to conventional motor training
Description: Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training compared to conventional motor training
Description: Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training compared to conventional motor training
Description: Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training compared to conventional motor training
Description: Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks.
Study: NCT03801551

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
Description: Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
Study: NCT01320280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 (Afatinib)
Description: 50 mg BIBW 2992 (Afatinib) tablets daily continuously
Study: NCT03122704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GBS screening
Description: Vaginal and anal swabs of patients will be screened for GBS screening
Study: NCT00758602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 0.75-1 g PO BID from Day 0 through Month 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 0.75-1 g PO BID from Day 0 through Month 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus, standard dose
Description: Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
Study: NCT03920826

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.